Revenue Breakdown
Composition ()
No data
Revenue Streams
Profitability & Margins
Evaluating the bottom line, Ocular Therapeutix Inc maintains a gross margin of 87.97%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -526.49%, while the net margin is -487.95%. These profitability ratios, combined with a Return on Equity (ROE) of -54.85%, provide a clear picture of how effectively OCUL converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, OCUL competes directly with industry leaders such as NKTR and OLMA. With a market capitalization of $1.95B, it holds a leading position in the sector. When comparing efficiency, OCUL's gross margin of 87.97% stands against NKTR's 100.00% and OLMA's N/A. Such benchmarking helps identify whether Ocular Therapeutix Inc is trading at a premium or discount relative to its financial performance.
